DOI: 10.1007/s00259-017-3667-7Pages: 1-2

Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

1. Houston Methodist Research Institute

2. Université de Bordeaux, Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL

3. Université de Bordeaux, CNRS/IN2P3, Centre d’Etudes Nucléaires de Bordeaux Gradignan (CENBG)

Correspondence to:
Paolo Zanotti-Fregonara
Email: pzfregonara@gmail.com

Close

Abstract

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Feb 24, 2017
  • Online: Mar 10, 2017

Article Tools

eanm
EJNMMI Ad